This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00022/identifier/drugbank/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00022/identifier/national-drug-code-directory/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/patent/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00022/identifier/uniprotkb/
n10http://www.drugs.com/cdi/
n21http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00022/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00022/identifier/pharmgkb/
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00022
rdf:type
n3:Drug
n3:description
Peginterferon alfa-2b is a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (PEG). The average molecular weight of the PEG portion of the molecule is 12,000 daltons. The average molecular weight of the PEG-Intron molecule is approximately 31,000 daltons. The specific activity of peginterferon alfa-2b is approximately 0.7 x 108 IU/mg protein. Interferon alfa-2b is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a strain of <i>Escherichia coli</i> bearing a genetically engineered plasmid containing an interferon gene from human leukocytes. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.
n3:dosage
n20:271B3FDF-363D-11E5-9242-09173F13E4C5 n20:271B3FE0-363D-11E5-9242-09173F13E4C5 n20:271B3FE1-363D-11E5-9242-09173F13E4C5 n20:271B3FDD-363D-11E5-9242-09173F13E4C5 n20:271B3FDE-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
The mean elimination half-life is approximately 40 hours (range 22 to 60 hours) in patients with HCV infection.
n3:indication
For the treatment of chronic hepatitis C in patients not previously treated with interferon alpha who have compensated liver disease and are at least 18 years of age.
owl:sameAs
n6:DB00022 n19:DB00022
dcterms:title
Peginterferon alfa-2b
adms:identifier
n12:Peginterferon_alfa-2b n14:PA164784024 n18:DB00022 n22:P01563 n24:0085-1323-01
n3:mechanismOfAction
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
n3:packager
n13:271B3FCD-363D-11E5-9242-09173F13E4C5 n13:271B3FCE-363D-11E5-9242-09173F13E4C5 n13:271B3FCB-363D-11E5-9242-09173F13E4C5 n13:271B3FCC-363D-11E5-9242-09173F13E4C5
n3:patent
n8:2329474 n8:1341567
n3:routeOfElimination
Renal elimination accounts for 30% of the clearance.
n15:hasAHFSCode
n17:08-18-20
foaf:page
n10:peginterferon-alfa-2b.html n21:peginterferon.htm
n3:Molecular-Weight
n4:271B3FE4-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:L03AB10
n3:absorption
Following a single subcutaneous dose of peginterferon alfa-2b, the mean absorption half-life (t&frac12; k<sub>a</sub>) was 4.6 hours.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
99210-65-8
n3:category
n3:clearance
* Oral cl=22 mL/hr∙kg [patients with HCV infection]
n3:containedIn
n7:271B3FDB-363D-11E5-9242-09173F13E4C5 n7:271B3FDC-363D-11E5-9242-09173F13E4C5 n7:271B3FD1-363D-11E5-9242-09173F13E4C5 n7:271B3FD2-363D-11E5-9242-09173F13E4C5 n7:271B3FCF-363D-11E5-9242-09173F13E4C5 n7:271B3FD0-363D-11E5-9242-09173F13E4C5 n7:271B3FD9-363D-11E5-9242-09173F13E4C5 n7:271B3FDA-363D-11E5-9242-09173F13E4C5 n7:271B3FD7-363D-11E5-9242-09173F13E4C5 n7:271B3FD8-363D-11E5-9242-09173F13E4C5 n7:271B3FD5-363D-11E5-9242-09173F13E4C5 n7:271B3FD6-363D-11E5-9242-09173F13E4C5 n7:271B3FD3-363D-11E5-9242-09173F13E4C5 n7:271B3FD4-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n4:271B3FE3-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B3FE2-363D-11E5-9242-09173F13E4C5